BAAT (Gene)

Organism:

Homo sapiens

Synonyms:BAAT, BACAT, BACD1, BAT, ENTREZ:570, HCHO, HGNC:932, MIM:602938, NM_001127610, NM_001374715, NM_001701, NP_001121082, NP_001361644, NP_001692, bile acid-CoA:amino acid N-acyltransferase

Omim:OMIM:602938

Id:ENSG00000136881

Hgnc:HGNC:932

Entrez:570

Ensembl:ENSG00000136881

Description:bile acid-CoA:amino acid N-acyltransferase

The protein encoded by this gene is a liver enzyme that catalyzes the transfer of C24 bile acids from the acyl-CoA thioester to either glycine or taurine, the second step in the formation of bile acid-amino acid conjugates. The bile acid conjugates then act as a detergent in the gastrointestinal tract, which enhances lipid and fat-soluble vitamin absorption. Defects in this gene are a cause of familial hypercholanemia (FHCA). Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View BAAT's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with BAAT.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using BAAT.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for BAAT.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with BAAT.

Results found

Linked to

	Label	Description
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE186471 1 V 2 CARNOSOL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE168596 2 V 3 ADIPONECTIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE125956 SYK knockdown 4 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE210655 3 V 2 CISPLATIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 10 V 6 TRAMETINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE208350 H-7 Huh-7 JHH-7 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE241036 0 V 1 ETHANOL MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE193541 nifurtimox A-549 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE168797 2 V 0 CANNABIDIOL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE239844 crizotinib 6 v 9 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE186471 1 V 2 CARNOSOL HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE168596 2 V 3 ADIPONECTIN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE125956 SYK knockdown 4 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE210655 3 V 2 CISPLATIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE213588 10 V 6 TRAMETINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE208350 H-7 Huh-7 JHH-7 0 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE241036 0 V 1 ETHANOL MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE193541 nifurtimox A-549 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE168797 2 V 0 CANNABIDIOL HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.